The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...
MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback